TX-SNOW-SOFTWARE
14.12.2022 17:01:37 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today released its latest survey which uncovers how IT decision makers’ priorities have shifted over the past 12 months and their top areas of focus as they head into 2023. The Snow Software 2023 IT Priorities Report polled 800 IT leaders from the United States, United Kingdom, Germany and Australia, and highlights that innovation remains a top priority for organizations (94%). However, reducing costs and managing security risks are competing for leaders’ attention and resources amid continuous market volatility.
Due to economic uncertainty and geopolitical disruptions upending the technology landscape, IT teams have shrinking or stagnant budgets and resources, yet the same goals and KPIs to meet. With increased pressure to foster innovation, boost productivity and remain competitive with fewer resources, IT leaders are struggling to identify where to put their time, energy and spend, resulting in continual strategy pivots.
Responding to Uncertainty in the Market
The report shows that economic uncertainty over the past year has forced nearly all IT leaders to rethink their strategy (80%), with 70% noting immense budget impacts.
When navigating resource reductions and market disruption, IT leaders rely on data and their previous experience to guide decision making. This is particularly true when taking risks and pursuing innovation initiatives, as data is needed to reinforce and rationalize prioritization when resources are limited. While IT leaders feel there is an abundance of data available to them, 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence.
Shifting Role of the CIO
Given technology deployments and data insights are often used to provide context through ongoing market volatility, many IT leaders are feeling the weight of their organization’s investments on their shoulders.
The role of the CIO has evolved significantly over the last three years, earning them decision making power not just around technology spend, but across the full scope and impact of the company’s bottom line. With this level of decision making power comes even greater accountability, and the same IT leaders who championed the shift to remote work are also at risk of becoming the scapegoats when businesses are not equipped for unprecedented events. CIOs and other IT leaders are living in an age of adaptation: new technologies, new market dynamics, new value drivers, and they are expected to successfully guide their organizations through a new reality of continual, crisis-fueled change.
“The reality is that IT isn’t going to get a break from the uncertainties impacting businesses anytime soon,” said Alastair Pooley, Chief Information Officer at Snow. “The IT leaders that push through the challenges with confidence all have one thing in common: the ability to access data and leverage it strategically. CIOs should not overlook the power of intelligence on their technology, given it empowers IT teams with data-driven insights to shift their focus from tactical response to strategic initiatives. This shift helps drive continued innovation through extended periods of uncertainty.”
Key Findings Include:
- Competing priorities are stalling IT teams’ ability to forward innovation. While innovation remains a priority for IT leaders, it is stalled as businesses wrestle with reducing cost (33%), managing security risks (28%) and advancing digital transformation (26%) – which leaves IT teams conflicted on where to focus their day-to-day efforts versus long-term strategic views.
- The role of the CIO is continuing to evolve. Over the past 18 months, 78% of respondents reported that the role has evolved immensely over this time. Further, 90% of CIOs say they are trusted advisors to the business, as opposed to a one-stop shop for technology. As expected, the evolution of their role has come with increased responsibilities, such as having more accountability for the financial impact of their IT investments (89%), as well as an expectation to innovate faster and demonstrate ROI (85%). CIOs are tasked with juggling many timely problems and priorities, all while ensuring they are meeting their individual goals and expectations.
- IT leaders are both thriving and drowning in data. The report reveals that 89% of IT leaders have access to actionable data to apply to decision making. However, 60% say they are overwhelmed by data, and 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence. A data-led approach is the most reliable way to navigate uncertainty, as it provides leaders with an evidence-based roadmap, as well as arming them with the confidence to make data-driven decisions, even in a rapidly changing environment. CIOs and IT leaders with threadbare teams and budgets will be challenged to do it all and need to rely on easily accessible data to drive optimal business decisions. In 2023, approaches like Technology Intelligence – or the ability to understand and manage all technology – will be the catalyst to continued success.
For more information about the latest version of the Snow annual report, please visit: https://www.snowsoftware.com/go/it-priorities/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
